Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 986780, 8 pages
http://dx.doi.org/10.1155/2015/986780
Research Article

CTLA4 Polymorphisms and De Novo Malignancy Risk after Renal Transplantation in Chinese Recipients

1Organ Transplantation Center, Shanghai First People’s Hospital, School of Medicine, Shanghai Jiao Tong University, 100 Haining Road, Shanghai 200080, China
2Key Laboratory of Systems Biology, Shanghai Advanced Research Institute (SARI), Chinese Academy of Sciences, 99 Haike Road, Shanghai 201210, China
3Department of Nephrology, Shanghai First People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China

Received 15 August 2014; Revised 28 November 2014; Accepted 30 November 2014

Academic Editor: Takuya Awata

Copyright © 2015 Yi-feng Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Yildirim, O. Ozyilkan, R. Emiroglu, B. Demirhan, H. Karakayali, and M. Haberal, “Early diagnosis of cancer in renal transplant patients: a single center experience,” Asian Pacific Journal of Cancer Prevention, vol. 7, no. 2, pp. 336–339, 2006. View at Google Scholar · View at Scopus
  2. J. M. Campistol, “Minimizing the risk of posttransplant malignancy,” Transplantation Proceedings, vol. 40, no. 10, pp. S40–S43, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. M.-L. Alegre, K. A. Frauwirth, and C. B. Thompson, “T-cell regulation by CD28 and CTLA-4,” Nature Reviews Immunology, vol. 1, no. 3, pp. 220–228, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. U. Grohmann, C. Orabona, F. Fallarino et al., “CTLA-4-Ig regulates tryptophan catabolism in vivo,” Nature Immunology, vol. 3, no. 11, pp. 1097–1101, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. K. Wing, Y. Onishi, P. Prieto-Martin et al., “CTLA-4 control over Foxp3+ regulatory T cell function,” Science, vol. 322, no. 5899, pp. 271–275, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. L. Bouqbis, H. Izaabel, O. Akhayat et al., “Association of the CTLA4 promoter region (-1661G allele) with type 1 diabetes in the South Moroccan population,” Genes and Immunity, vol. 4, no. 2, pp. 132–137, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. H. Ueda, J. M. M. Howson, L. Esposito et al., “Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease,” Nature, vol. 423, no. 6939, pp. 506–511, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. Y. Gorgi, I. Sfar, T. B. Abdallah et al., “CTLA-4 Exon 1 (+49) and promoter (−318) gene polymorphisms in kidney transplantation,” Transplantation Proceedings, vol. 38, no. 7, pp. 2303–2305, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. Wu, J.-L. Tang, S.-J. Wu, H.-Y. Lio, and Y.-C. Yang, “Functional polymorphism of CTLA-4 and ICOS genes in allogeneic hematopoietic stem cell transplantation,” Clinica Chimica Acta, vol. 403, no. 1-2, pp. 229–233, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. Ö. Tapirdamaz, V. Pravica, H. J. Metselaar et al., “Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation,” Gut, vol. 55, no. 6, pp. 863–868, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. L. Wang, G. Su, X. Zhao et al., “Association between the cytotoxic T-lymphocyte antigen 4 +49A/G polymorphism and bladder cancer risk,” Tumor Biology, vol. 35, no. 2, pp. 1139–1142, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. V. Bharti, B. K. Mohanti, and S. N. Das, “Functional genetic variants of CTLA-4 and risk of tobacco-related oral carcinoma in high-risk North Indian population,” Human Immunology, vol. 74, no. 3, pp. 348–352, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. M. Yang, T. Sun, Y. Zhou et al., “The functional cytotoxic T lymphocyte-associated Protein 4 49G-To-A genetic variant and risk of pancreatic cancer,” Cancer, vol. 118, no. 19, pp. 4681–4686, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. Zheng, X. Yu, L. Jiang et al., “Association between the Cytotoxic T-Lymphocyte Antigen 4 +49G > A polymorphism and cancer risk: A meta-analysis,” BMC Cancer, vol. 10, article 522, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. T. Sun, Y. Zhou, M. Yang et al., “Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer,” Cancer Research, vol. 68, no. 17, pp. 7025–7034, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. Y. Zhang, J. Zhang, Y. Deng et al., “Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and cancer risk: a meta-analysis,” Cancer, vol. 117, no. 18, pp. 4312–4324, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. L. C. Racusen, R. B. Colvin, K. Solez et al., “Antibody-mediated rejection criteria—an addition to the Banff ′97 classification of renal allograft rejection,” American Journal of Transplantation, vol. 3, no. 6, pp. 708–714, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Guo, Y. Fan, J. Qiu, Y. Liu, J. Gao, and F. Guo, “Polymorphisms in CTLA4 influence incidence of drug-induced liver injury after renal transplantation in Chinese recipients,” PLoS ONE, vol. 7, no. 12, Article ID e51723, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. F. Faul, E. Erdfelder, A.-G. Lang, and A. Buchner, “G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences,” Behavior Research Methods, vol. 39, no. 2, pp. 175–191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. G. C. L. Johnson, L. Esposito, B. J. Barratt et al., “Haplotype tagging for the identification of common disease genes,” Nature Genetics, vol. 29, no. 2, pp. 233–237, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. T. Kouki, Y. Sawai, C. A. Gardine, M.-E. Fisfalen, M.-L. Alegre, and L. J. DeGroot, “CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease,” The Journal of Immunology, vol. 165, no. 11, pp. 6606–6611, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. C.-S. Lee, Y. J. Lee, H.-F. Liu et al., “Association of CTLA4 gene A-G polymorphism with rheumatoid arthritis in Chinese,” Clinical Rheumatology, vol. 22, no. 3, pp. 221–224, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. G. Végso, M. Tóth, M. Hídvégi et al., “Malignancies after renal transplantation during 33 years at a single center,” Pathology & Oncology Research, vol. 13, no. 1, pp. 63–69, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Y. Chen, X. Yao, Y. Y. Chen, and J. X. Jiang, “Clinical study of malignancy in renal allograft recipients,” Journal of Clinical Urology, no. 18, pp. 144–145, 2003 (Chinese). View at Google Scholar
  25. M. Q. Peng, Z. H. Yang, and Z. L. Fang, “An assemble analysis of malignancy following renal transplantation in China,” Chinese Journal of Organ Transplantation, vol. 26, no. 5, pp. 269–271, 2005. View at Google Scholar
  26. F. Tremblay, M. Fernandes, F. Habbab, M. D. B. de Edwardes, R. Loertscher, and S. Meterissian, “Malignancy after renal transplantation: incidence and role of type of immunosuppression,” Annals of Surgical Oncology, vol. 9, no. 8, pp. 785–788, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. D. C. Jin, Y. S. Yoon, S. A. Yoon, Y. S. Kim, B. K. Bang, and Y. B. Koh, “Ten cases of malignancies in kidney allografts,” Transplantation Proceedings, vol. 26, no. 4, pp. 1975–1976, 1994. View at Google Scholar · View at Scopus
  28. K. Yokota, M. Fukumitsu, K. Kuzuhara et al., “Development of cancer in renal allograft recipients,” Transplantation Proceedings, vol. 26, no. 4, pp. 1977–1978, 1994. View at Google Scholar · View at Scopus
  29. A. Gutierrez-Dalmau and J. M. Campistol, “Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review,” Drugs, vol. 67, no. 8, pp. 1167–1198, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. J.-P. Cosyns, M. Jadoul, J.-P. Squifflet, P.-J. Van Cangh, and C. Van Ypersele de Strihou, “Urothelial malignancy in nephropathy due to Chinese herbs,” The Lancet, vol. 344, no. 8916, p. 188, 1994. View at Google Scholar · View at Scopus
  31. D. B. Aaron, M. Bernard, R. B. Shpiner, M. S. Levine, D. A. Peguesb, and M. S. Litwinc, “Transitional cell carcinoma of the bladder two years after successful lung transplantation: case report and review of the literature,” Urology, vol. 59, no. 2, 296 pages, 2002. View at Publisher · View at Google Scholar
  32. C.-H. Liao, S.-C. J. Chueh, M.-K. Lai, and J. Chen, “Transitional cell carcinoma in renal transplant recipients,” Transplantation Proceedings, vol. 36, no. 7, pp. 2152–2153, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. B. D. Kahan, “Sirolimus: a ten-year perspective,” Transplantation Proceedings, vol. 36, no. 1, pp. 71–75, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. R. Marcén, J. Pascual, A. M. Tato et al., “Influence of immunosuppression on the prevalence of cancer after kidney transplantation,” Transplantation Proceedings, vol. 35, no. 5, pp. 1714–1716, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. H. M. Kauffman, W. S. Cherikh, M. A. McBride, Y. Cheng, and D. W. Hanto, “Post-transplant de novo malignancies in renal transplant recipients: the past and present,” Transplant International, vol. 19, no. 8, pp. 607–620, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. B. L. Kasiske, J. J. Snyder, D. T. Gilbertson, and C. Wang, “Cancer after kidney transplantation in the United States,” American Journal of Transplantation, vol. 4, no. 6, pp. 905–913, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. N. A. Bakker, G. W. Van Imhoff, E. A. M. Verschuuren et al., “HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical,” Transplantation, vol. 80, no. 5, pp. 595–599, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. H. M. Ramsay, A. A. Fryer, C. M. Hawley, A. G. Smith, D. L. Nicol, and P. N. Harden, “Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia,” Journal of the American Academy of Dermatology, vol. 49, no. 3, pp. 397–406, 2003. View at Publisher · View at Google Scholar · View at Scopus